Affimed in the spotlight (part VIII)
Boutique data analysis of results presented at the American Association for Cancer Research (AACR) Annual Meeting 2022
Affimed & MD Anderson reported an update on their AFM13+NK cell program. The data was very promising and exceeded expectations with continued dose response and durability. Here we present a technical deep-dive on this data:
The Data
Overall, in all doses, 17/19 (90%) patients reported responses, with 10CR and 7PR.
The more interesting data came from …